insights_auto
Why is ABVX down 3,67%?
Dive Deeperchevron_right
ABVX:EPA
Abivax SA
78,70 €
arrow_downward
-3,67%(-3,00) 1D
23-окт., 17:35:27 GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ABVX...
Open
80,90 €
High
81,15 €
Low
78,05 €
Mkt. cap
6,82 млд
Avg. vol.
124,60 миң
Volume
74,87 миң
52-wk high
139,00 €
52-wk low
60,45 €
EPS
-5,20 €
Shares outstanding
87,55 млн
No. of employees
98
Open
80,90 €
High
81,15 €
Low
78,05 €
Mkt. cap
6,82 млд
Avg. vol.
124,60 миң
Volume
74,87 миң
52-wk high
139,00 €
52-wk low
60,45 €
EPS
-5,20 €
Shares outstanding
87,55 млн
No. of employees
98
News stories
From web sources and news partners
www.foreignpolicyjournal.com
·
5 мүнөт мурун
Canadian Publishers Push Back Against Meta Platforms (NASDAQ: META) Over AI Content Scraping Terms
FinanceFeeds
·
40 мүнөт мурун
Nasdaq: Microsoft and Alphabet Report Hours After Fed Decision, Amazon on 29 October - After a 0.7% Losing Week
Yahoo Finance
·
5 саат мурун
I'd Put Most of a Lump Sum Into an S&P 500 Fund Right Away. Here's When I Wouldn't.
Bloomberg.com
·
1 күн мурун
SpaceX in Talks to Access 80,000 Cell Sites for New Network
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Employees98
Founded2013-ж., 4-дек.
Headquarters-
Sector-
Websiteabivax.com